Stability studies in oncology
European Journal of Oncology Pharmacy · 2019
DOI: 10.1097/op9.0000000000000012 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Oncology Pharmacy, 2019. Verfasst von Jean Vigneron und 2 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Hospital pharmacists, physicians, and nurses need stability information on the drugs used in their daily practice. The objectives of this work were to evaluate if the information given by pharmaceutical companies about the stability of reconstituted and diluted solutions in the field of oncology were sufficient in the daily practice of hospitals.
Methods
The first step was to establish a list of the main needs about stability data on the basis of the daily practice of hospital pharmacists. The second step was to search through information given by pharmaceutical companies and then to compare to hospital pharmacists’ needs. The third step was to find information in the cases, in which pharmaceutical companies’ information was not sufficient.
Results
The situation is different depending on the product. For originators, stability data given by pharmaceutical companies are often very limited, the goal being to obtain the marketing authorization. For generics or biosimilars, extended stability studies are carried out to conquer the market and are part of the marketing strategy. A list of studies to fill the gap of companies’ information was presented. Examples including bortezomib, rituximab, azacitidine, nivolumab, and some mixtures were presented. The importance of stability studies conducted in hospitals is emphasized.
Conclusion
Pharmaceutical companies perform stability studies for their products and for their own interest. In many cases, the results of these studies are insufficient and do not meet the need for information that hospital pharmacists are looking for. Conducting stability studies by hospital pharmacy teams should be encouraged.
Zitieren
APA
Vigneron, J., D’Huart, E., & Demoré, B. (2019). Stability studies in oncology. European Journal of Oncology Pharmacy. https://doi.org/10.1097/op9.0000000000000012
Vancouver
Vigneron J, D’Huart E, Demoré B. Stability studies in oncology. European Journal of Oncology Pharmacy. 2019. doi:10.1097/op9.0000000000000012
BibTeX
@article{Vigneron2019,
author = {Vigneron, Jean and D’Huart, Elise and Demoré, Béatrice},
title = {Stability studies in oncology},
journal = {European Journal of Oncology Pharmacy},
year = {2019},
doi = {10.1097/op9.0000000000000012}
}
EUVIMED